Capricor Duchenne cell therapy shows positive results, potentially reversing FDA rejection and quadrupling shares.
Author: PharmaSignal News Desk
Pharvaris Phase 3 Success marks a significant milestone in hereditary angioedema treatment, potentially impacting over 8,000 patients in Europe.
Richard Pazdur retirement from FDA’s CDER marks a significant leadership change in 2025.
FDA animal testing guidance reduces non-human primate use, aiding U.S. drugmakers amid global competition.
Janux prostate cancer data reveals a lower response rate, impacting its clinical trial progress.
Contingent value rights are increasingly used in biotech deals, bridging price gaps amid market turbulence.
UK drug price deal allows the country to avoid US tariffs by adjusting pricing rules for new medicines.
Belite Stargardt drug shows promising results in a late-stage trial, positioning it for potential regulatory approval.
Protego amyloidosis drug receives $130M funding to develop a new treatment for light chain amyloidosis, aiming to improve patient outcomes.
Novartis job cuts impact Swiss manufacturing, affecting hundreds of employees. Novo’s diabetes drug advances to Phase 3 trials. #Novartis #JobCuts #DiabetesDrug #PharmaSignal